Search - tctmd.com

Displaying 921 - 940 of 6943

Sort: Relevancy | Date

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

October 27, 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

News Conference News TCT 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

Michael O'Riordan

October 26, 2023

CLASP IID at 1 Year: Good Results With Both Pascal, MitraClip for Mitral TEER

News Conference News TCT 2023

CLASP IID at 1 Year: Good Results With Both Pascal, MitraClip for Mitral TEER

October 26, 2023

ALIGN-AR: Positive Results for Trilogy Valve in Aortic Regurgitation

News Conference News TCT 2023

ALIGN-AR: Positive Results for Trilogy Valve in Aortic Regurgitation

October 26, 2023

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

News Conference News TCT 2023

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

Michael O'Riordan

October 25, 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

News Conference News TCT 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

October 25, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

October 24, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

Sham Procedures in CV Research: What’s Sacrificed for Science?

News Daily News

Sham Procedures in CV Research: What’s Sacrificed for Science?

October 23, 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

News Conference News TCT 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

October 23, 2023

For Predicting CV Risk, Life’s Essential 8 Doesn’t Add Much to Simple 7

News Daily News

For Predicting CV Risk, Life’s Essential 8 Doesn’t Add Much to Simple 7

October 23, 2023

Earlier Extraction for Cardiac Device Infections Tied to Lower Mortality

News Daily News

Earlier Extraction for Cardiac Device Infections Tied to Lower Mortality

October 20, 2023

SAVR 5-Year Survival Tops 92% in Low-Risk Patients: STS Registry

News Daily News

SAVR 5-Year Survival Tops 92% in Low-Risk Patients: STS Registry

Yael L. Maxwell

October 20, 2023

What’s Going to Be Hot at TCT 2023

News Opinion Editor's Corner

What’s Going to Be Hot at TCT 2023

October 19, 2023

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

October 18, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.